@pelositrackerJul 9, 2026 · 2:51 PM

This is why we do it Back in April, we flagged Cisneros buying $BBIO ahead of an FDA decision Today, a rival company's heart drug failed a major clinical trial. That leaves BridgeBio as one of the only approved treatments for the same patients Since that tweet, it's up ~20% and just hit all time highs He still hasn't sold his pharma picks: • $AGIO is up +27% • $RARE is up +50% since the tweet

@adamfeuersteinApr 28, 2026 · 1:23 PM

Third and final $PFE tafamidis patent lawsuit dismissed. $BBIO up

@adamfeuersteinFeb 12, 2026 · 12:37 PM

BridgeBio $BBIO drug for genetic cause of dwarfism succeeds in key study This is the third consecutive Phase 3 success for BridgeBio. It also could spell trouble for $BMRN's competing dwarfism drug. https://t.co/mwnbVetPFy via @damiangarde

@adamfeuersteinOct 29, 2025 · 11:12 AM

$BBIO Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 https://t.co/R6UndoW0DS

@adamfeuersteinOct 27, 2025 · 11:02 AM

BridgeBio $BBIO study data on drug for rare form of muscular dystrophy could set up approval https://t.co/S4LRPEh4sb via @Jasonmmast